Restrata
Commercial- Indications
- Wound management, Surgical wounds, Traumatic wounds
Company intelligence / Profile preview
Acera Surgical
St. Louis, Missouri, United Statesacera-surgical.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Acera Surgical has commercialized FDA-cleared products based on its proprietary electrospun fiber matrix technology. Clinical evidence supports the effectiveness of Restrata in wound management and soft-tissue repair, with Level I clinical data available for some applications. Cerafix was the first fully synthetic dura substitute cleared in the U.S.
- Therapeutic areas
- OtherDermatologyNeurology
- Modalities
- DeviceSynthetic biomaterial matrix (Electrospun fiber matrix)
- Industry
- Implantable Medical Devices
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Acera Surgical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acera Surgical.